Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

doi:10.1016/j.eururo.2017.12.001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

European urology - 1 May 2018

Galsky Matthew D, Wang Huan, Hahn Noah M, Twardowski Przemyslaw, Pal Sumanta K, Albany Costantine, Fleming Mark T, Starodub Alexander, Hauke Ralph J, Yu Menggang, Zhao Qianqian, Sonpavde Guru, Donovan Michael J, Patel Vaibhav G, Sfakianos John P, Domingo-Domenech Josep, Oh William K, Akers Nicholas, Losic Bojan, Gnjatic Sacha, Schadt Eric E, Chen Rong, Kim-Schulze Seunghee, Bhardwaj Nina, Uzilov Andrew V

Abstract excerpt

BACKGROUND: Chemotherapy may exert immunomodulatory effects, thereby combining favorably with the immune checkpoint blockade. The pharmacodynamic effects of such combinations, and potential predictive biomarkers, remain unexplored. OBJECTIVE: To determine the safety, efficacy, and immunomodulatory effects of gemcitabine and cisplatin (GC) plus ipilimumab and explore the impact of somatic DNA damage response gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Deoxycytidine

Share to Disease-Free Survival

Share to Gemcitabine

Share to Ipilimumab

Share to Neoplasm Invasiveness

Share to Urologic Neoplasms

Source

Open in PubMed

Identifiers

PMID: 29248319
DOI: 10.1016/j.eururo.2017.12.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.PMID 29248319Read ↗

Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.Semantic proximity Read ↗

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.Semantic proximity Read ↗

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.Semantic proximity Read ↗

DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypesSemantic proximity Read ↗

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.Semantic proximity Read ↗

Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.Semantic proximity Read ↗

Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor typesSemantic proximity Read ↗

Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Semantic proximity Read ↗

Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.Semantic proximity Read ↗

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.Semantic proximity Read ↗

Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."Semantic proximity Read ↗

Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.